This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan 17;156(2):JC1-7.

doi: 10.7326/0003-4819-156-2-201201170-02007.

Insulin secretagogues were associated with increased mortality compared with metformin in type 2 diabetes

Gabriela Prutsky¹, Juan Pablo Domecq, Apostolos Tsapas

Affiliations

PMID: 22250169
DOI: 10.7326/0003-4819-156-2-201201170-02007

Comment

Insulin secretagogues were associated with increased mortality compared with metformin in type 2 diabetes

Gabriela Prutsky et al. Ann Intern Med. 2012.

. 2012 Jan 17;156(2):JC1-7.

doi: 10.7326/0003-4819-156-2-201201170-02007.

Authors

Gabriela Prutsky¹, Juan Pablo Domecq, Apostolos Tsapas

Affiliation

¹ Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 22250169
DOI: 10.7326/0003-4819-156-2-201201170-02007

No abstract available

PubMed Disclaimer

Comment on

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Schramm TK, et al. Eur Heart J. 2011 Aug;32(15):1900-8. doi: 10.1093/eurheartj/ehr077. Epub 2011 Apr 6. Eur Heart J. 2011. PMID: 21471135

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Atypon